RIGL PEER ANALYSIS

Rigel Pharmaceuticals Inc — metric-by-metric comparison with peers and the industry median

RIGLRigel Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

RIGLIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	RIGL	MSB	TLX	RTALB	CSL	Ind. Median
P/E	2.32●	—	—	4.92	30.04	18.00
P/B	2.11	—	6.26	0.61●	2.25	3.60
EV/EBITDA	5.67●	—	118.24	75.02	10.37	15.20
P/S	2.82	30.99	3.18	6.71	2.67●	10.43

Financial Health
Metric	RIGL	MSB	TLX	RTALB	CSL	Ind. Median
Current Ratio	2.62●	—	1.43	1.21	2.57	5.90
Debt/Equity	11.4%	—	112.3%	1.2%●	67.4%	10.9%
NetDebt/EBITDA	-0.77●	—	13.13	0.90	2.22	1.15

Profitability
Metric	RIGL	MSB	TLX	RTALB	CSL	Ind. Median
Net Margin	121.5%	-115.3%	-0.9%	136.3%●	9.2%	-125.7%
ROE	174.1%●	-11.3%	-1.8%	15.1%	7.7%	-47.5%
ROA	107.0%●	-8.6%	-0.7%	13.1%	3.8%	-35.8%
EBITDA Margin	43.8%●	-76.6%	3.0%	9.0%	32.8%	-105.8%

Growth + Dividend
Metric	RIGL	MSB	TLX	RTALB	CSL	Ind. Median
Rev. Growth	47.6%	410.4%●	56.3%	24.0%	4.8%	5.1%
NI Growth	879.7%●	—	—	134.0%	-39.4%	12.1%
Div. Yield	—	0.0%	—	0.0%	2.5%●	0.2%
Payout	—	0.0%	—	0.0%	103.1%	0.0%

Valuation
Metric	RIGL	XOMA	ACRS	CRMD	RGNX	ZVRA	Ind. Median
P/E	2.32●	24.87	—	4.54	—	—	18.00
P/B	2.11	6.94	4.94	1.88●	37.87	4.32	3.60
EV/EBITDA	5.67	16.22	—	3.70●	—	—	15.20
P/S	2.82	21.63	84.83	2.05●	9.09	—	10.43

Financial Health
Metric	RIGL	XOMA	ACRS	CRMD	RGNX	ZVRA	Ind. Median
Current Ratio	2.62	3.59	4.03	2.98	2.62	4.89●	5.90
Debt/Equity	11.4%	110.5%	1.4%	33.2%	337.1%	0.6%●	10.9%
NetDebt/EBITDA	-0.77●	0.59	1.46	-0.16	0.35	—	1.15

Profitability
Metric	RIGL	XOMA	ACRS	CRMD	RGNX	ZVRA	Ind. Median
Net Margin	121.5%●	87.0%	-832.6%	45.2%	-330.2%	—	-125.7%
ROE	174.1%●	31.9%	-48.4%	65.6%	-196.4%	—	-47.5%
ROA	107.0%●	13.0%	-35.1%	37.5%	-69.6%	—	-35.8%
EBITDA Margin	43.8%	138.4%●	-843.9%	53.2%	-261.2%	—	-105.8%

Growth + Dividend
Metric	RIGL	XOMA	ACRS	CRMD	RGNX	ZVRA	Ind. Median
Rev. Growth	47.6%	-3.3%	-52.9%	384.6%●	-44.0%	—	5.1%
NI Growth	879.7%	—	—	953.6%●	—	—	12.1%
Div. Yield	—	0.7%	—	—	—	—	0.2%
Payout	—	17.5%	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on RIGL

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 8, 26. This content is for informational purposes only and is not investment advice.